LDN-214117 – 25 mg

Brand:
Cayman
CAS:
1627503-67-6
Storage:
-20
UN-No:
Non-Hazardous - /

Bone morphogenetic proteins (BMPs) are secreted signaling proteins, many of which are involved in various developmental processes, in addition to bone formation. Activation of BMP type I receptors, also known as activin receptor-like kinases (ALK1-7), leads to the assembly of SMAD complexes, which translocate to the nucleus to induce transcriptional activation important for normal development and tissue repair. LDN-214117 is a selective BMP type I receptor kinase ALK1 and ALK2 inhibitor (IC50s = 24 nM for each).{30971} It demonstrates preference for ALK1 and ALK2 over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-β, respectively).{30971}  

 

Available on backorder

SKU: - Category:

Description

A selective ALK1 and ALK2 inhibitor (IC50s = 24 nM for each) with preference over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-β, respectively)


Formal name: 1-​[4-​[6-​methyl-​5-​(3,​4,​5-​trimethoxyphenyl)​-​3-​pyridinyl]​phenyl]​-piperazine

Synonyms: 

Molecular weight: 419.5

CAS: 1627503-67-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Activin-like Kinases (ALKs)||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling